

USSN - 10/071,214

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (currently amended). A ~~non-human~~ transgenic mouse, having integrated within its genome a nucleotide sequence (SCCE-construct) comprising ~~(i)~~ a heterologous nucleotide sequence coding for a human stratum corneum chymotryptic enzyme (SCCE), operably linked to a SV40 early promoter that drives expression of said heterologous sequence ~~(i)~~ in skin, wherein the mouse exhibits epidermal hyperplasia and hyperkeratosis and a mild cellular inflammatory reaction of the skin.

2 (currently amended). A ~~non-human~~ transgenic mouse according to claim 1 wherein said operably linked SV40 early promoter drives expression of *scce* in epidermis.

3-10 (cancelled).

11 (currently amended). A ~~non-human~~ transgenic mouse according to claim 1, wherein the DNA sequence codes for the human SCCE corresponding to amino acid no. 23 through no. 253 of the amino acid sequence shown in SEQ ID NO. 2.

12 (currently amended). A ~~non-human~~ transgenic mouse according to claim 1, wherein the DNA sequence codes for the human SCCE corresponding to amino acid no. 30 through no. 253 of the amino acid sequence shown in SEQ ID NO. 2.

13 (currently amended). A ~~non-human~~ transgenic mouse according to claim 1, wherein the DNA sequence codes for the human SCCE shown in SEQ ID NO. 2.

14 (cancelled).

15 (currently amended). A ~~non-human~~ transgenic mouse according to claim 1, wherein the heterologous nucleotide sequence is SEQ ID NO:1.

16-28 (cancelled).

USSN - 10/071,214

29 (currently amended). A method for making a transgenic non-human mouse according to claim 1, the method comprising

(a) constructing and amplifying said ~~heterologous~~ nucleotide sequence (SCCE-construct),

(b) introducing said ~~heterologous~~ nucleotide sequence (SCCE-construct) into a cell from a mouse, where said cell is selected from the group consisting of a mouse ovum, a mouse embryonic cell, and a mouse embryonic stem cell,

(c) using said cell or the progeny of said cell to create a number of putative transgenic non-human mice, and

(d) selecting said non-human mouse having said ~~heterologous~~ nucleotide sequence (SCCE-construct) integrated within its genome.

30 (currently amended). A method for making a transgenic non-human mouse according to claim 29 wherein said operably linked promoter drives expression of *scce* in epidermis.

31 (cancelled).

32 (previously presented). A method according to claim 29 comprising introducing the SCCE-construct into an ovum or embryo of the mouse.

33 (previously presented). A method according to claim 29 comprising microinjecting the SCCE-construct into embryonal stem cells of the mouse.

34 (previously presented). A method according to claim 29 comprising microinjecting the SCCE-construct into C57BL/6JxCBA-f2 mouse ova or embryos.

35 (previously presented). A method according to claim 29 comprising introduction of the SCCE-construct into C57BL/6JxCBA-f2 mouse ova or embryos and breeding the resulting mice with

USSN - 10/071,214

C57BL/6JxCBA or with C57BL/6J to obtain transgenic progeny and stable mouse lines.

36-43 (cancelled)

44 (withdrawn). A method of identifying a compound or composition effective for the prevention or treatment of an abnormal or unwanted phenotype, the method comprising

(a) administering a compound or composition to a transgenic mouse according to claim 1,

(b) evaluating the appearance of the relevant organ and/or the behavior of a mouse treated according to step (a), and

(c) comparing the appearance of the relevant organ and/or the behavior of a treated mouse with an untreated control mammal,

(d) identifying the compound or composition as being effective for the prevention or treatment of the abnormal or unwanted phenotype.

45-46 (cancelled).

47 (withdrawn). A method according to claim 44 of identifying a compound or composition effective for the prevention or treatment of inflammatory skin diseases selected from the group of diseases consisting of epidermal hyperkeratosis, acanthosis, epidermal inflammation, dermal inflammation and pruritus.

48 (withdrawn). A method according to claim 44 of identifying a compound or composition effective for the prevention or treatment of atopic dermatitis or eczema.

49 (withdrawn). A method according to claim 44 of identifying a compound or composition effective for the prevention or treatment of acne.

50 (withdrawn). A method according to claim 44 of identifying a compound or composition effective for the prevention or treatment of inherited skin diseases with epidermal hyperkeratosis.

51 (withdrawn). A method according to claim 44 of

USSN - 10/071,214

identifying a cosmetic composition.

52-69 (cancelled).

70 (previously presented). The method of claim 29 in which said introduction is by electroporation, transfection, microinjection or viral infection.

71 (previously presented). The method of claim 29 in which said introduction is by microinjection.

72 (previously presented). The method of claim 71 in which the microinjection is into a mouse ovum.